Modified-Release Oral Minoxidil for Consistent Hair Regrowth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, such as topical minoxidil, often result in rapid absorption and short half-life, leading to fluctuating serum levels and potential adverse effects, while oral minoxidil formulations lack controlled release mechanisms to maintain effective hair regrowth promotion.
Innovation Solution
A modified release oral formulation of minoxidil or its pharmaceutically acceptable salts, designed to release 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, providing sustained serum levels for hair regrowth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical minoxidil is used for hair loss treatment, then hair regrowth promotion is achieved, but rapid absorption and short half-life cause fluctuating serum levels and adverse effects
Solution Approach 1:
The patent applies dynamics by transitioning from static topical application to dynamic controlled-release oral delivery. The modified-release formulation dynamically adjusts minoxidil release rates to maintain stable serum concentrations, eliminating the fluctuating levels caused by rapid topical absorption while sustaining therapeutic efficacy for hair regrowth.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of minoxidil delivery by using modified-release formulations with specific release profiles (50-90% release over 8-12 hours, Tmax of 30-360 minutes, Cmax of 0.25-20 ng/ml). This parameter transformation converts rapid absorption into controlled, sustained release, reducing adverse effects while maintaining therapeutic benefits.
2Ease of operation
If oral minoxidil formulations are used, then systemic delivery is achieved, but lack of controlled release mechanisms fails to maintain effective hair regrowth promotion
Solution Approach 1:
The patent applies segmentation by dividing the oral minoxidil formulation into modified-release components that segment the release profile into controlled phases. This segmentation ensures sustained effective concentrations over extended periods (8-12 hours), maintaining hair regrowth promotion throughout the dosing interval rather than allowing rapid clearance.
3Speed
If rapid absorption formulations are used, then quick onset of action is achieved, but short half-life causes fluctuating serum levels
Solution Approach 1:
The patent implements continuity of useful action through modified-release formulations that provide continuous, controlled minoxidil release over 8-12 hours. This continuous release maintains stable serum levels throughout the dosing period, eliminating the fluctuations caused by rapid absorption followed by quick elimination, while still achieving adequate onset speed for therapeutic effect.
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.